ProShares Ultra Health Care ETF

Algert Global LLC Boosts Stake in Eli Lilly and Company

The GLP-1 Channel War: Competition Intensifies Between Eli Lilly and Novo Nordisk in the Weight-Loss Drug Market

Lilly to allocate 97% of its Korea investment to clinical trials to establish a global hub.

Lilly expected to release key clinical trial results for its triple-agonist drug, retatrutide

FDA target approval date for Eli Lilly's oral GLP-1 drug, orforglipron

Eli Lilly to Participate in BioVaria Partnering Event in Munich, Germany

Clough Capital Partners L P Significantly Reduces Stake in UnitedHealth Group by 80.2%

Chevy Chase Trust Holdings LLC Cuts Holdings in UnitedHealth Group by 5.3%

Investment firm Clear Street Group acquires a new stake in UnitedHealth Group, purchasing shares worth approximately $294 million

Eli Lilly Becomes Market Focus Due to GLP-1 Expansion Plan in China

Senator Markwayne Mullin discloses purchase of UnitedHealth Group stock

Eli Lilly to Participate in the ChinaBIO Partnering Forum 2026

Lilly USA President to deliver keynote on access in obesity management at Reuters Events Pharma USA 2026

Eli Lilly announces a $3 billion investment in China over the next ten years to upgrade its supply chain

UnitedHealth Group to pay a quarterly dividend of $2.21 per share

Eli Lilly Issues Safety Warning on Compounded Versions of its Drug Mounjaro

Eli Lilly Issues Safety Warning and Seeks Recall for Compounded Versions of its Weight-Loss Drug Zepbound

FDA expected to make approval decision on Lilly's oral obesity drug orforglipron

Ausdal Financial Partners Inc. increases its stake in Eli Lilly and Company by 42.1%

UnitedHealth Group begins restoring the Change Healthcare payment platform disrupted by a cyberattack.

bioAffinity Tech

Firefly Neuroscience

Silvaco

eLong Power

T-REX 2X Long UPXI Daily Target ETF

Polaryx Therapeutics

TCW Strategic Income Fund, Inc.

Stak

iSpecimen

Oruka Therapeutics

GILD

LLYX

PILL

IBBQ

SBIO

Eli Lilly, AbbVie, Abbott Laboratories, Pfizer, Gilead Sciences, Bristol Myers Squibb, and Vertex Pharmaceuticals are the top pharmaceutical stocks to watch today, as identified by MarketBeat's stock screener. These companies are notable for their significant trading volumes and are involved in the research, development, and sale of prescription drugs. Investors monitor various factors such as drug pipelines and regulatory approvals that can impact stock volatility and long-term value.

- Eli Lilly and Company, AbbVie, Abbott Laboratories, Pfizer, Gilead Sciences, Bristol Myers Squibb, and Vertex Pharmaceuticals are highlighted as top pharmaceutical stocks by MarketBeat.  
- These companies are involved in various treatments ranging from diabetes and cancer to infectious diseases, with significant trading volume observed recently.  
- Investors are advised to monitor these stocks due to their volatile nature influenced by drug pipelines, regulatory approvals, and clinical trial results.

Market Beat

Proshares Ultra Nasdaq Biotech

Gilead Sciences

Defiance Daily Target 2X Long LLY ETF

Invesco Biotechnology & Genome ETF

Vertex Pharma

VanEck Biotech ETF

Abbott Laboratories

First Trust NYSE Arca Biotech Index Fd

Direxion Pharma & Medical Bull 3X

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

VG Health

Bristol Myers Squibb

ALPS Medical Breakthrough

Pfizer

Direxion Daily LLY Bear 1X Shares

Direxion Daily LLY Bull 2X Shares

Abbvie

iShares US Pharma

Health Care Select Sector SPDR

iShares Biotechnology ETF

Eli Lilly

SPDR S&P Biotech

Top Pharmaceutical Stocks To Watch Today - March 14th

CURE

UBS Group has raised its target price for Molina Healthcare (NYSE:MOH) from $145.00 to $151.00, maintaining a "neutral" rating. This suggests a potential upside of 1.16% from the stock's previous close. Other analysts have varied opinions, with price targets ranging from $109.00 to $224.00. Molina Healthcare's stock recently traded at $149.27, with a market cap of $7.69 billion. The company reported a revenue of $11.38 billion for the last quarter, exceeding estimates, but missed earnings expectations. Institutional investors hold 98.50% of the company's stock.

Molina Healthcare

iShares US Healthcare Providers

SPDR S&P Health

Direxion Healthcare Bull 3X

UBS Group Forecasts Strong Price Appreciation for Molina Healthcare (NYSE:MOH) Stock

ARKG

- A trial comparing blood thinners Eliquis and Xarelto found that Eliquis has a significantly lower risk of dangerous bleeding in patients with blood clots.  
- The study involved 2,760 participants and indicated no significant difference in the risk of recurrent blood clots between the two drugs.  
- Additionally, changes in the aging gut were linked to cognitive decline in mice, suggesting potential for new treatments targeting gut-brain communication.

Reuters

SPDR S&P Health Equip

iShares Global Healthcare

Johnson & Johnson

Bayer

Ark Genomic Revolution ETF

iShares US Medical Devices

Health Rounds: Eliquis proves safer than Xarelto for patients with deep blood clots

In Thursday's intraday session, several health care stocks experienced significant movements. Notable gainers included Bristol-Myers Squibb (up 34.2% to $0.14), Codexis (up 33.85% to $1.7), and Agape ATP (up 23.5% to $5.15). Conversely, Incannex Healthcare saw a decline of 38.0% to $3.7, while Acurx Pharmaceuticals fell 24.38% to $4.56. Other notable losers included Rapid Micro Biosystems (down 21.58% to $3.44) and Polaryx Therapeutics (down 20.49% to $4.58).

benzinga_article

Codexi

Acurx Pharmaceuticals

Agape ATP

Rapid Micro Biosystems

Incannex Healthcare

12 Health Care Stocks Moving In Thursday's Intraday Session

Century Therapeutics

Century Therapeutics 2025 net loss narrows beating estimates

- Major drugmakers, including Pfizer and Teva, failed to disqualify attorney Joseph Nielsen, who represents insurers suing them over alleged price-fixing in antitrust lawsuits.  
- U.S. District Judge Cynthia Rufe ruled that Nielsen can continue his role, rejecting claims that he poses a risk of using confidential information from his previous position as a state prosecutor.  
- The case centers on allegations against pharmaceutical companies for colluding to inflate drug prices, with Nielsen emphasizing adherence to ethical conduct rules regarding confidential information.

Teva Pharmaceutical Industries

Humana

Pfizer, Teva lose bid to disqualify ex-prosecutor in generic drug price‑fixing case

LABD

BioNTech co-founders Uğur Şahin and Özlem Türeci will step down to launch a new mRNA-focused venture as the company reported a 57% rise in net losses for 2025. Their departure marks a significant change for BioNTech, which saw its share price peak during the Covid-19 pandemic. The company is now targeting oncology to improve its financial performance, with ongoing Phase II and III programs. Analysts express mixed feelings about the leadership change, but note the potential of BioNTech's pipeline and partnerships, including a significant collaboration with Bristol Myers Squibb.

Pharmaceutical Technology

Direxion S&P Biotech Bear 3X

BioNTech SE

BioNTech co-founders step down to launch new mRNA venture

Richard Bernstein Advisors LLC has reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 60.9% in Q3, now holding 26,104 shares valued at $1.18 million. Other institutional investors have also adjusted their positions, with significant increases and new stakes. Bristol Myers Squibb's stock opened at $60.11, with a market cap of $122.41 billion. The company reported Q4 earnings of $1.26 per share, missing estimates, and announced a quarterly dividend of $0.63 per share, yielding 4.2%. Positive developments in clinical trials may enhance future revenue potential.

Richard Bernstein Advisors LLC Lowers Position in Bristol Myers Squibb Company $BMY

RIVN

Wall Street analysts have upgraded several stocks, including CrowdStrike (CRWD), Alector (ALEC), Rivian (RIVN), Solaredge (SEDG), and Dianthus (DNTH). Notably, Morgan Stanley upgraded CRWD from Equal-Weight to Overweight with a price target increase from $487 to $510. Other upgrades include Alector to Buy with a $6 target, Rivian to Buy with a $20 target, Solaredge to Neutral with a $40 target, and Dianthus to Strong Buy with a $123 target. Analysts suggest considering CRWD for investment.

Rivian Automotive

CrowdStrike

GraniteShares 2x Long CRWD Daily ETF

GraniteShares 2x Long RIVN Daily ETF

This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Molina Healthcare Inc. (MOH) shares rose 1.08% to $146.03 on a positive trading day, outperforming competitors like Humana Inc. and Centene Corp., which saw declines. The S&P 500 Index increased by 0.83%, while the Dow Jones Industrial Average rose by 0.50%. Despite the gain, Molina's stock remains 59.43% below its 52-week high of $359.97 reached on April 4th. Trading volume was 1.2 million, below the 50-day average of 1.7 million.

Dow Jones

Centene

Molina Healthcare Inc. Stock Outperforms Competitors On Strong Trading Day

Bristol Myers Squibb announced that its blood cancer treatment candidate, oral mezigdomide, showed positive results in a late-stage trial. The drug, when combined with carfilzomib and dexamethasone, significantly improved progression-free survival in patients with relapsed or refractory multiple myeloma compared to existing treatments. The company's chief medical officer expressed excitement about the results, emphasizing the potential for effective oral treatment options for challenging blood cancers.

MorningStar

Bristol Myers Squibb Says Blood-Cancer Treatment Performed Well in Late-Stage Trial

Bristol Myers Squibb (BMY) announced positive interim Phase 3 results from the SUCCESSOR-2 study, showing that oral mezigdomide combined with carfilzomib and dexamethasone significantly improves progression-free survival in patients with relapsed or refractory multiple myeloma compared to carfilzomib and dexamethasone alone. The safety profile aligns with existing data on mezigdomide. The study continues to monitor patient survival and safety outcomes.

rttnews

Bristol Myers Squibb Announces Positive Phase 3 Results For Mezigdomide In Multiple Myeloma

Bristol's cancer drug meets main goal in late-stage trial

Bristol Myers Squibb (BMS) has received FDA approval for Sotyktu (deucravacitinib), an oral selective TYK2 inhibitor, to treat adults with active psoriatic arthritis (PsA). This is the first TYK2 inhibitor approved for this indication. The approval is based on Phase III studies showing significant improvements in disease activity. Common side effects include acne and upper respiratory infections. Sotyktu was previously approved for moderate-to-severe plaque psoriasis. BMS emphasizes its role in managing psoriatic disease symptoms and plans further development in other conditions.

BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment

ProShares Ultra Health Care ETF(RXL.US)

Top Pharmaceutical Stocks To Watch Today - March 14th

UBS Group Forecasts Strong Price Appreciation for Molina Healthcare (NYSE:MOH) Stock

Health Rounds: Eliquis proves safer than Xarelto for patients with deep blood clots

12 Health Care Stocks Moving In Thursday's Intraday Session

Century Therapeutics 2025 net loss narrows beating estimates